There were 1,363 press releases posted in the last 24 hours and 429,986 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image